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Abstract
 
Though used occasionally, systemic therapies in severe childhood psoriasis have
not been systematically investigated. Cyclosporin A (CysA) is effective in adults
with severe psoriasis but there are no extensive data regarding the efficacy and
safety of its use in childhood psoriasis. In this paper, we describe six children
aged between 11 months and 13 years (average: 7.6 years) treated with CysA
microemulsion formulation for severe psoriasis, who had been unresponsive
to other treatments. The CysA dose ranged from 2 to 4 mg/kg/day, for periods
varying from 8 to 105 weeks (mean: 54 weeks). Dose tapering was gradual
after lesion improvement and adjusted according to clinical response. Adjuvant
therapy with topical steroids, vitamin D3 ointments, coal tar preparations or
anthralin was used in all children. Acitretin was used in three patients for short
periods. The children were regularly monitored for serum renal and liver
function and blood pressure. Improvement of skin lesions was achieved after
between 4 and 30 (mean: 12) weeks of treatment, with complete remission
in three children. Relapse of lesions occurred in the other children during CysA
reduction, but they responded to a dose increase. The treatment was found to
be well tolerated and with no significant side-effects. CysA can be used in
carefully selected and monitored patients and may represent an alternative
tool for severe episodes of psoriasis in children, when other therapies are
unsuccessful.
 
Introduction
 
Childhood psoriasis has many clinical facets that may
change over time. Although its exact incidence is un-
known
 
1
 
 it has been calculated to range from 0.1 to 3%
 
2
 
 in
various parts of the world. In children, psoriasis usually
both follows a benign course and is successfully managed
with topical agents. In severe forms of the disease, such
as generalized pustular psoriasis, extensive psoriasis
vulgar, psoriatic erythroderma or psoriatic arthropathy,
more aggressive treatments, such as phototherapy or
systemic therapy, are required.
 
3
 
 However, because of
the uncommon nature of these psoriasis types, the clinical
experience with systemic agents is limited.
Primary systemic treatments for severe psoriasis
include phototherapy, retinoids, methotrexate (MTX),
cyclosporin (CyA) and new biological therapies. Psoralen
plus ultraviolet A (PUVA) therapy is not indicated in
children, although narrowband ultraviolet B (UVB) in
older children has recently proven to be a safer alternative
to maintain long-term disease control.
 
4
 
 Retinoids are
the most commonly used oral medication, but the risk of
skeletal toxicity, derangement of hepatic enzymes and
serum lipids and mucocutaneous side-effects are a
limiting factor.
 
5–7
 
 MTX remains one of the most effective
antipsoriatic drugs, but previous experience of its use
in childhood psoriasis is scarce and there are concerns
over long-term safety concerning its hepatotoxic potential
and the risk of bone marrow suppression.
 
8,9
 
The safety and efficacy of CyA therapy has been
extensively studied in severe adult and childhood atopic
dermatitis and in adult psoriasis. The most troublesome
side-effects of CyA are nephrotoxicity and hypertension,
both of which are of particular concern in long-term use.
These side-effects are dose-dependant and, in almost
all cases, reversible after discontinuation of CyA. Provided
the patient is monitored for side-effects, treatment can
be continued for up to 2 years.
 
10
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Previous experience with CyA use in childhood psoria-
sis has been controversial. Mahé 
 
et al
 
.
 
11
 
 described four
children, aged between 2 and 10 years, who were treated
with CyA for severe drug resistant psoriasis and in
whom the results were unsatisfactory. Only one child
inadvertently treated with 10 mg/kg/day showed response,
but the therapy was discontinued due to relapse. Perret
 
et al
 
.
 
12
 
 describe three children, aged between 7 and 11
years, with generalized plaque psoriasis, who responded
well to CyA without side-effects, except for nausea
and diarrhoea in one child at the beginning of treatment.
Most of the case reports of successful use of CyA in pae-
diatric groups involve patients with pustular psoriasis,
with a well tolerated and effective treatment.
 
13–15
 
We describe six children, five boys and one girl, aged
between 11 months and 13 years (average: 7.6 years), with
severe psoriasis, refractory to conventional therapy
and treated with CyA microemulsion formulation. Five
children presented generalized plaque psoriasis and one,
pustular psoriasis. All children had previously failed to
respond to topical treatments and two did not respond to
UVB (one in association with acitretin). In all children
the treatment was considered to be well tolerated and
with no significant side-effects.
 
Clinical cases
 
Patient 1
 
A 6-year-old boy with a 12 month widespread psoriasis
affecting the upper and lower limbs, trunk, face and
scalp (fig. 1). The initial PASI was 22.9. His psoriasis was
precipitated by surgery (circumcision). There was no
history of sore throat or other focal infections that might
have precipitated exacerbations of the disease. He had
been treated with topical preparations (emollients, coal
tar, calcipotriol and anthralin), with no response. CysA
was started at a dose of 3.8 mg/kg daily and, after 45 days
of treatment, a marked lesion improvement was observed
(fig. 2). The dosage was reduced, with complete remission
of lesions after 60 days of treatment and without relapses
during the 1 year of follow-up. During CyA treatment, no
abnormalities were found in blood pressure or renal
function.
 
Patient 2
 
A 12-year-old boy with generalized plaque psoriasis
involving the trunk, limbs and scalp, over the last
12 months. The initial PASI was 29. There was no
history of sore throat or other focal infections that might
have precipitated exacerbations of the disease. He had
been treated with various topical preparations,
including emollients, betamethasone valerate, tacalcitol
and anthralin, without remission. A course of ultraviolet
B for 2 months resulted in little improvement of lesions.
He then started CyA treatment at a dose of 2.7 mg/kg
daily. Two months after starting CyA, his skin significantly
improved and the dosage was gradually reduced. He
remained in almost complete remission for the following
12 months, with only a few localized lesions on the scalp,
which is managed well with topical coal tar and steroid
lotion. His renal function and blood pressure remained
stable throughout the course of treatment.
 
Patient 3
 
An 11-year-old boy with a 2-year history of chronic
plaque psoriasis covering most of his body, arms, legs and
scalp. The initial PASI was 36.4. The child came from a
fig. 1 Psoriasis unresponsive to topical therapy (patient 1).
fig. 2 Lesion resolution after 45 days of cyclosporin A treatment.
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difficult social background and there was a family history
of psoriasis from his father’s side. There was no history of
sore throat or other focal infections that might have
precipitated exacerbations of the disease. He had been
treated with various topical preparations, including
emollients, calcipotriol, betamethason and coal tar. None
of these resulted in satisfactory control of his psoriasis.
CyA was started at a dose of 2.5 mg/kg/day. He showed a
transitory improvement of lesions, but 6 months later,
during dose reducing, he was admitted because of the
development of a generalized exfoliative erytroderma.
The CyA dose was increased to 4 mg/kg/day, with great
improvement of lesions after 5 weeks of treatment.
Tapering of the dosage resulted in a relapse of psoriasis.
The dosage was reverted and acitretin associated at a dose
of 0.2 mg/kg/day, with good response after 6 weeks. Dose
tapering was gradual with good control of the disease.
During CyA treatment no abnormalities were found in
blood pressure, complete blood count, liver function,
serum electrolytes, serum urea and creatinine tests.
 
Patient 4
 
A 3-year-old boy with generalized plaque psoriasis,
involving the trunk, the limbs and the scalp, poorly
controlled with topical corticosteroids over the last 12
months (fig. 3). He had a history of atopic dermatitis from
the age of 10 months, which responded well to topical
corticosteroids, emollients and antihistamines. The initial
PASI was 31.6. There was no history of sore throat or
other focal infections that might have precipitated
exacerbations of the disease. CyA was initiated at a dose
of 3.5 mg/kg/day, with significant improvement after
3 months (fig. 4). The dosage was then gradually reduced,
with no relapse. He is currently almost disease-free,
after 24 months of follow-up, with no adverse effects
on blood pressure or renal function.
 
Patient 5
 
A 13-year-old boy with widespread erythematous
plaques of psoriasis affecting the trunk, limbs and scalp
over the last 12 months. The initial PASI was 41.3. There
was no history of sore throat or other focal infections
that might have precipitated exacerbations of the disease.
He had previously failed to respond to topical therapy.
He was then started on CyA at a dose of 3.5 mg/kg/day,
with improvement of lesions after 2 months. The dosage
was discontinued, but the lesions promptly began to
relapse. The dosage was reverted to 3.5 mg/kg daily and
his lesions cleared after 6 weeks of treatment. Six months
later, he had a lesion relapse that responded to a course
of CyA at a dose of 3.5 mg/kg/day and acitretin at
0.2 mg/kg/day and control of his disease was achieved
after 5 months of treatment. He was disease-free for
6 months. He experienced no side-effects and his liver
and renal function, serum lipids and blood pressure
remain stable.
fig. 3 Psoriasis unresponsive to topical therapy (patient 4).
fig. 4 Lesion resolution after 12 weeks of cyclosporin A treatment.
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Patient 6
 
An 11-month-old girl with generalized pustular
psoriasis since the age of 2 months. She had recurrent
episodes of multiple erythematous and scaly plaques
with overlying pustules on the scalp, face, trunk and
extremities (fig. 5). During acute flares the child was
ill, with malaise, anorexia and pain secondary to her
exfoliating skin. She also had a history of severe ery-
thematous nappy rash and complete dystrophic finger
nails and toenails. A lesional biopsy showed changes
consistent with pustular psoriasis. Other investigations,
including full blood count and biochemical profile, were
at normal range and her HLA type was A24, B35, 58, CW
07,12. Various topical treatments were unhelpful. She
started CyA at a lower dosage of 2 mg/kg/day, with
improvement of lesions after 3 months (fig. 6). Over the
next year the child had three episodes of disease exac-
erbation, responding well to CyA. In the later episode,
we added acitretin at 0.3 mg/kg/day for 2 months, with
faster improvement of lesions and no side-effects. Two
years after starting CyA, the treatment was discontinued
because she had an acute flare that did not respond to
conventional doses of CyA. During CyA treatment, no
abnormalities were found in blood pressure, complete
blood count and liver or renal function.
 
Discussion
 
Systemic treatment is usually reserved for the man-
agement of children with severe subtypes of psoriasis,
including those with recalcitrant plaque psoriasis, which
does not respond to topical and phototherapy. Usually,
in these cases, we tend to first use retinoids, based on
the experience acquired with this drug in children with
keratinization disorders. However, patients receiving
oral retinoids are at risk of several skeletal complications
including hyperostotic changes, calcification of tendons
and ligaments and premature closure of epiphysis.
 
7
 
Skeletal abnormalities may be asymptomatic, irreversible
and not associated with laboratory alterations.
 
16
 
 Therefore,
close monitoring of growth parameters and yearly
radiology studies are recommended during the duration
of retinoid treatment. Other adverse effects observed
are mucocutaneous (chapped lips, dry skin, nose bleeds),
and elevation of lipid and liver enzymes, and these
parameters must be regularly monitored. If used carefully,
the retinoids are probably safe but, in monotherapy, is
only partially effective and rarely clears the disease. In
fact, two of our children did not respond to UVB, one
in association with acitretin.
Compared with other current systemic therapies, such
as acitretin in monotherapy, CyA proved to be signifi-
cantly more efficacious.
 
17
 
 CyA has not been systematically
investigated in paediatric populations with psoriasis, but
the drug has been studied extensively in paediatric atopic
dermatitis.
 
18–20
 
 There is also accumulated experience
on the prevention and treatment of organ transplant
rejection.
 
21
 
 CyA has been shown to be well tolerated
in children with connective tissue disease
 
22
 
 and diabetes
mellitus.
 
23
 
 Some of these studies, carried out in children
with atopic dermatitis, are open and blind clinical trials
that show that the drug is consistently safe. These studies
also suggest that CyA is well tolerated both by children
and by adults. In addition, the most serious side-effects,
nephrotoxicity and hypertension, can be controlled by
patient monitoring, with appropriate dose adjustment or
pharmacological intervention. Prevention or reversibility
of side-effects may be achieved by discontinuation of
therapy after the induction of clearing.
fig. 5 Pustular psoriasis in an 11-month-old child (patient 6). fig. 6 Lesion improvement after 12 weeks of cyclosporin A treatment.
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The dosage for childhood psoriasis has been empirically
developed and extrapolated from results in adults, which
have recommended an initial dose of 3–4 mg/kg/day. If
no significant response is found after 6–8 weeks, the dose
can be titrated up to 5 mg/kg/day. In our experience, the
initial doses within 2–4 mg/kg/day have offered good
results; these are in a similar range to those used by other
authors.
 
12,14
 
 None of our children took a dose higher than
4 mg/kg/day and all the children had a good initial
response. Therefore, we found that low to moderate
doses can be effective in clearing psoriasis. In fact, with
these doses, we observed a satisfactory improvement
of skin lesions and, indeed, three children maintained
a good response to CyA, without relapses after reduction
of dosage. The other children experienced deterioration
in their psoriasis on tapering of the CyA, but control
of the disease was rapidly achieved after reverting to the
original dosage. Although some children had relapse
after treatment, it was particularly encouraging that
the treatment period could provide a useful period of
remission. In fact, three children had complete remission
during the subsequent 12–24 months follow-up period
and two children that relapsed with the tapering doses
have not suffered any major relapses 6–12 months after
discontinuation of CyA. Patient 6 had had an atypical
and particularly severe form of pustular psoriasis (com-
plete nail dystrophy, continued flares since the age of 2
months) that responded to CyA during two consecutive
years.
Some studies have demonstrated pharmacokinetic
differences between children and adults. In children,
oral absorption may be lower, clearance is more rapid
and volume distribution at a steady state is greater.
 
11,24
 
Because of a dose-dependant effect, cases of childhood
psoriasis may require higher dosages of CyA, or doses
should be administered three times per day.
 
11,24
 
 However,
in cases of atopic dermatitis, despite the pharmacokinetic
differences between adults and children, the same
dosage of CyA, 2.5–5 mg/kg/day, is equally effective.
 
18
 
Adverse effects of CyA are common, usually dose-
related and can be serious. Consequently, the lowest
possible maintenance dose and shortest treatment period
should be implemented. The side-effects of most concern
are decreased renal function and hypertension. The risk of
CyA-induced nephropathy can be reduced by avoiding
doses exceeding 5 mg/kg/day and elevations in serum
creatinine greater than 30% above baseline.
 
25
 
 These
side-effects are relatively infrequent and rarely require
withdrawal of treatment. Our children tolerated CyA
extremely well, with no significant side-effects. The
length of time during which our children took CyA varied
from 8 to 105 weeks (mean: 54 weeks); one child took
CyA for more than a year and two children continued
maintenance therapy for 2 years. None of our children
experienced a persistent elevation of blood pressure or serum
creatinine. Moreover, we did not observe other possible
side-effects associated with the use of CyA, such as nausea,
diarrhoea, joint pains, muscle aches tremors, headache,
paresthesias, gingival hyperplasia or hypertrichosis.
In childhood atopic dermatitis, there is limited experi-
ence in long-term use of CyA. One study demonstrated
that CyA was effective and safe in controlling severe
atopic dermatitis in children over a 1-year period.
 
19
 
 There
were no significant changes in either blood pressure or
serum creatinine levels with a dosage of 5 mg/kg/day.
Although children seem to tolerate CyA better than
adults, treatment for periods of longer than 2 years should
be avoided because of cumulative toxicity.
The risk of developing malignancies, skin cancers and
lymphoproliferative disorders, an especially worrisome
prospect for children, is increased in transplant patients
treated with high-dose, long-term CyA.
 
26
 
 For dermatolog-
ical conditions, the risk of malignancies does not appear
to be increased in patients receiving doses of 5 mg/kg/day
or less in patients who are not on concomitant immuno-
suppressives.
 
27
 
 However, this risk is another reason to
minimize the dose and duration of treatment.
Concomitant treatment, either with topical steroids,
vitamin D3 ointments, coal tar preparations or anthralin,
was used in all children in our study. Combination with
topical agents has been used with varying efficacy and
safety, with the potential benefit of reducing the dosage
and/or the treatment duration. Although the number of
studies that show the efficacy of CyA in combination
with other agents is limited, topical steroid
 
28
 
 anthralin
 
29
 
and calcipotriol
 
30
 
 have been reported as improving its effi-
cacy. It is our opinion that the child should be encour-
aged to maintain topical therapy.
In three children that relapsed with the tapering
dose, we added acitretine for short periods, with the view
of improving the treatment efficacy without CyA dose
increase. This combination was associated with significant
clinical improvement and did not increase its toxicity.
Combination with retinoids is not only effective but may
also protect against cutaneous malignancies.
 
31
 
 Moreover,
this combination can potentially reduce the dosage of
CyA required or the duration of the treatment and
therefore minimize the risk of side-effects.
We suggest that, when systemic treatment is indicated
in childhood psoriasis, CyA should be considered as a
treatment option, along with retinoids and MTX. CyA can
be used in carefully selected and monitored patients
and represents an alternative tool for severe episodes of
psoriasis in children, refractory to topical therapy. In its
favour, it appears to be more effective than other current
therapies, has less side-effects than the retinoids, which are
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poorly tolerated because of mucocutaneous side-effects,
and is therefore more acceptable to patients. In view of
the potential toxicity of CyA use, further studies are
needed to find out more about the optimal dosage, treat-
ment duration and appropriate monitoring. Gradual
tapering is the most appropriate method of withdrawing
CyA and this is also worthy of further investigation.
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